Prostate cancer

EA8183

A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis

Trial overview

Topic

EA8183

Disease

Prostate cancer

Description

Primary Objective:To determine whether 12 months (52 weeks) of androgen deprivation therapy (ADT) and darolutamide improves metastasis-free survival (MFS) compared to 12 months (52 weeks) of ADT plus placebo in men with high risk prostate cancer (defined by CAPRA-S score ≥3 and a high Decipher score (>0.6) (C3+D+)) who have undergone radical prostatectomy.

Contact

Michigan

Maria Pappas

Florida

Peggy Mouradian

Physicians

Thomas Boike

MD

Radiation Oncologist

Clarkston (Radiation oncology) +3

Larry L. Kestin

MD, FACR, FASTRO

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Eduardo B. Fernandez

MD, PhD, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +3

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +1